Session 5: Abstracts and ongoing trials session

N. Cooper, M. Michel

Oral communications

OC1 - A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH CHRONIC IMMUNE THROMBOCYTOPENIA (AVA-PED-301)
R.F. Grace
OC3 - WHOLE EXOME SEQUENCING OF PATIENTS WITH ADULT ONSET EVANS SYNDROME: A COHORT OF 120 PATIENTS
E. Crickx
OC4 - THE ROLE OF GENETIC SEQUENCING IN THE DIAGNOSTIC WORK UP FOR CHRONIC IMMUNE THROMBOCYTOPENIA
N. Joshi
OC5 - COGNITIVE IMPAIRMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
C. Vladescu
OC6 - USE OF SECOND-LINE TREATMENTS IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN EUROPE. A PARALLEL STUDY IN SIX PROSPECTIVE MULTICENTER NATIONAL REGISTRIES
G. Moulis
OC7 - PRECLINICAL CHARACTERIZATION OF PIRTOBRUTINIB, A NON-COVALENT (REVERSIBLE) BRUTON TYROSINE KINASE INHIBITOR, IN ITP
T..J. Gonzalez-Lopez
Posters

P01 - PHASE 4 ADOPT STUDY: INTERIM ANALYSIS OF EFFICACY AND SAFETY RESULTS OF AVATROMBOPAG TREATMENT IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA
M.T. Álvarez Román
P02 - A EUROPEAN RETROSPECTIVE STUDY TO DESCRIBE REAL-WORLD OUTCOMES IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA TREATED WITH AVATROMBOPAG: INTERIM RESULTS
F. Zaja
P03 - UPDATE ON ITP PATIENTS TREATED WITH AVATROMBOPAG: A REAL-LIFE MONOCENTRIC EXPERIENCE
S. D'Angelo
P04 - FOSTAMATINIB IN POLYMORBID CARDIOVASCULAR PATIENTS: WHEN AND WHOM? A MONOCENTRIC REAL LIFE EXPERIENCE
C. Giubbilei
P05 - THE OCCURANCE OF THROMBOSIS IN ITP PATIENTS ON TPORAS IN ROYAL UNITED HOSPITAL, BATH, UK
B. Bentil-Tumil
P06 - ASSESSING REFERRAL AND CORTICOSTEROID INITIATION PATTERNS IN ISOLATED THROMBOCYTOPENIA: A 2023 PATIENT COHORT STUDY AT THE ROYAL UNITED HOSPITAL, BATH
W. Hwessa
P07 - CONTRIBUTION OF THE INTESTINAL MICROBIOTA AND THE OXIDATION-REDUCTION SYSTEM IN STABILIZING PLATELET (PLT) COUNT IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
G. Tolomelli
P08 - IMMUNE THROMBOCYTOPENIA AND IMMUNOGLOBULIN G4-RELATED DISEASE: IS THERE A CORRELATION?
D. Lame
P09 - IMPACT OF THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) TREATMENT AND ADHERENCE IN PATIENTS (PTS) WITH PRIMARY CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN INTERNATIONAL CROSS-SECTIONAL SURVEY
J.J. Zwaginga
Privacy Policy | Cookie Policy